Abstract 6258: Development of humanized patient-derived xenograft models for triple negative breast cancer

Her, Yujeong; Son, Hye Yeon; Kim, Ju Hee; Heo, Woo Hang; Quan, Mingji; Li, Songbin; Moon, Hye-Jin

doi:10.1158/1538-7445.am2022-6258

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on recent advances in humanized mouse models of CD34+ HSCs, a wide variety of studies on the first humanized mouse models of related cancers have emerged. The first humanized mouse model of CD34+ HSCs was established for the study of adrenocortical carcinoma, 87 nasopharyngeal carcinoma, 88 myelofibrosis, 89 estrogen receptor‐positive metastatic 90 and triple‐negative breast cancer, 91 and ovarian cancer 92 . Notably, in the context of the COVID‐19 pandemic, Sefik et al produced a new coronal humanized mouse using adeno‐associated virus to transport human ACE2 to the lungs of humanized mice of M‐CSF h/h IL‐3/GM‐CSF h/h SIRPA h/m TPO h/h Rag2 null /Il2Rγc null (MISTRG6) strain 93 .…”

Section: Humanized Mouse Modelsmentioning

confidence: 99%

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

Wang,

Li,

Lin

et al. 2023

Anim Models and Exp Med

View full text Add to dashboard Cite

Patient‐derived tumor xenograft (PDX) models, a method involving the surgical extraction of tumor tissues from cancer patients and subsequent transplantation into immunodeficient mice, have emerged as a pivotal approach in translational research, particularly in advancing precision medicine. As the first stage of PDX development, the patient‐derived orthotopic xenograft (PDOX) models implant tumor tissue in mice in the corresponding anatomical locations of the patient. The PDOX models have several advantages, including high fidelity to the original tumor, heightened drug sensitivity, and an elevated rate of successful transplantation. However, the PDOX models present significant challenges, requiring advanced surgical techniques and resource‐intensive imaging technologies, which limit its application. And then, the humanized mouse models, as well as the zebrafish models, were developed. Humanized mouse models contain a human immune environment resembling the tumor and immune system interplay. The humanized mouse models are a hot topic in PDX model research. Regarding zebrafish patient‐derived tumor xenografts (zPDX) and patient‐derived organoids (PDO) as promising models for studying cancer and drug discovery, zPDX models are used to transplant tumors into zebrafish as novel personalized medical animal models with the advantage of reducing patient waiting time. PDO models provide a cost‐effective approach for drug testing that replicates the in vivo environment and preserves important tumor‐related information for patients. The present review highlights the functional characteristics of each new phase of PDX and provides insights into the challenges and prospective developments in this rapidly evolving field.

show abstract